Mineralys officer plans $85K stock option sale

Officer Daphne Karydas has filed a Rule 144 notice to sell 3,000 MLYS shares via broker-assisted cashless option exercise, following a prior 3,000-share sale in June 2026.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. (MLYS) is the issuer of common stock that officer Daphne Karydas plans to sell under Rule 144. The notice covers a planned sale of 3,000 shares of common stock on September 15, 2026, through a broker-assisted cashless exercise of employee stock options handled by Merrill Lynch.

These planned sales are in addition to a prior sale of 3,000 shares of common stock on June 17, 2026, for proceeds of $75,000 during the preceding three months.

Key Figures

Planned shares to be sold: 3,000 shares Approximate value of planned position: $85,740.00 Shares sold in past 3 months: 3,000 shares +3 more

6 metrics

Planned shares to be sold 3,000 shares Common stock planned sale on September 15, 2026 via cashless option exercise

Approximate value of planned position $85,740.00 Value associated with 3,000 shares of Mineralys Therapeutics, Inc. common stock

Shares sold in past 3 months 3,000 shares Common stock sale on June 17, 2026 reported in the three-month lookback

Proceeds from prior sale $75,000.00 Sale of 3,000 shares of common stock on June 17, 2026

Planned sale date September 15, 2026 Date of planned sale and option exercise for 3,000 shares

Prior sale date June 17, 2026 Date of 3,000-share sale in the past three months

Key Terms

Rule 144, broker assisted cashless exercise, exercise of employee stock options, common stock

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

broker assisted cashless exercise financial

"Broker assisted cashless exercise"

exercise of employee stock options financial

"Exercise of employee stock options"

common stock financial

"Common Stock | 09/15/2026 | Exercise of employee stock options"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing indicate for Mineralys Therapeutics, Inc. (MLYS)?

The Form 144 notice states that officer Daphne Karydas plans to sell 3,000 shares of Mineralys Therapeutics, Inc. common stock on September 15, 2026, in connection with the exercise of employee stock options through a broker-assisted cashless exercise.

How many MLYS shares are planned to be sold under this Rule 144 notice?

The notice covers a planned sale of 3,000 shares of Mineralys Therapeutics, Inc. common stock, associated with the exercise of employee stock options on September 15, 2026.

What is the approximate value of the MLYS shares covered by the planned sale?

The securities information section shows an approximate value of $85,740.00 for the 3,000 shares of Mineralys Therapeutics, Inc. common stock referenced in the planned sale handled by Merrill Lynch.

Which broker is involved in the planned MLYS share sale by Daphne Karydas?

The planned sale of 3,000 MLYS shares on September 15, 2026 is to be handled by Merrill Lynch, located at 225 Liberty Street, New York, as a broker-assisted cashless exercise of employee stock options.

Have any MLYS shares been sold by this person in the past three months?

Yes. The filing reports that 3,000 shares of Mineralys Therapeutics, Inc. common stock were sold on June 17, 2026, with proceeds of $75,000.00 during the previous three months.

On which market is Mineralys Therapeutics, Inc. common stock referenced in this notice traded?

The securities information identifies the common stock as traded on NASDAQ in connection with the 3,000-share position and its indicated value of $85,740.00.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:20 PM Accepted by SEC EDGAR 09/15/2026 - 04:19 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001816952
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Mineralys Therapeutics, Inc.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	Karydas Daphne
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	3000	85740.00	88406885	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/15/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			3000	09/15/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daphne Karydas 150 N. RADNOR CHESTER RD. SUITE F200 RADNOR, PA 19087	Common Stock	06/17/2026	3000	75000.00

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/22/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daphne Karydas
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)